Introduction
The widespread use of antiretroviral therapy (ART) in developed countries has modified HIV infection from a terminal illness to a chronic infection [1] . Considerable evidence suggests that progressive damage occurs to multiple organ systems (including brain) despite viral suppression and immune recovery. Neurocognitive impairment (NCI) in HIV-infected adults occurs as a spectrum of disorders that have been categorized as asymptomatic neurocognitive impairment (ANI), mild neurocognitive disorder (MND) and HIV-associated dementia (HAD) [2] . Neurocognitive impairment remains a major cause of morbidity in the modern treatment era (prevalence between 15 and 55%) with the majority of neurocognitive impaired adults in the ANI and MND groups [3, 4] . Although ANI does not affect daily functioning, patients with ANI are two to six times more likely to progress to symptomatic MND or HAD [5] .
HIV enters the central nervous system (CNS) soon after infection [6, 7] , and the brain is a site of chronic infection [8] . ANI and MND are associated with immune [9] [10] [11] and cytokine activation [12, 13] , metabolic disturbances [14] [15] [16] [17] [18] , accumulations of bioactive lipids such as ceramide, and sterol markers of cell stress [19, 20] ; many of which worsen with age and duration of infection [11, 18, 19, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] . Despite the considerable literature describing consequences of HIV infection in the CNS, few studies have determined the temporal relationship of inflammatory, stress, and metabolic changes to neurocognitive performance. Here we used cerebrospinal fluid (CSF) to conduct an informatics analysis of the CSF protein content in groups of HIVþ adults selected to differ by longitudinal changes in neurocognitive performance and found that upregulation of acute phase and complement systems preceded worsening cognitive function, whereas downregulation of acute phase and complement pathways preceded and was sustained during neurocognitive improvement.
Materials and methods
Patients and sample collection CSF samples were obtained from the Central Nervous System HIV Anti-Retroviral Therapy Effects Research and the HIV Neurobehavioral Research Center studies. Patient selection was based on a case review of $3500 clinical visits from 430 study participants as previously described [35, 36] . Patients had complete clinical and neuropsychological data available and were on stable ART for at least 3 months before the first visit and for the duration of the observation period (a single-drug modification in ART was allowed if within the same drug class). Participants were demographically matched with the exception of group differences in current CD4 þ cell count and CSF storage time (Table S1 , http:// links.lww.com/QAD/B90).
Change in neurocognitive status
The neuropsychological testing battery was conducted by trained neuropsychometricians and consisted of tests covering seven cognitive domains including: executive function, learning and delayed recall, working memory, verbal fluency, speed of information processing, and motor skills [37] . The best available normative standards were used to convert the scores into demographically corrected standard scores (T-scores), which correct for effects of age, education, sex, and ethnicity. The presence and severity of NCI was determined using the Global Deficit Score (GDS) approach, in which a GDS of at least 0.5 was impaired [38] . All follow-up visits were corrected for practice effects [39] . Neurocognitive change was determined using a multivariable change score approach as previously described [35, 40] . Z-scores were generated for each of 15 neuropsychological test variables, and then summed to provide a summary regression score. A change in cognitive status from visit 1 to visit 2 was generated for each patient, and they were grouped as Declining (normal cognitive status or neurocognitive impairment that then worsened over time, n ¼ 22), Improving (neurocognitive impairment at baseline that improved by visit 2, n ¼ 20), Stably Impaired (neurocognitive impairment that was stable over time, n ¼ 22), or Stably Normal (no neurocognitive impairment at either visit, n ¼ 25) based on changes in the summary regression score. Neurocognitive test data from a third visit were used to ensure that changes in cognitive status were not transient.
Standard protocol approvals, registrations, and patient consents
The collection and use of human samples was approved by the Institutional Review Board at each study site. All participants provided informed consent for all study procedures, including future use of their stored specimens and data for research.
Sample preparation and mass spectrometry Immunodepletion of CSF was accomplished using the ProteoPrep Immunoaffinity Albumin & IgG Depletion kit (Sigma PROTIA-1KT; Sigma, St Louis, Missouri, USA) [41] . Samples were methanol extracted, vortexed, and stored in À80 8C overnight to allow precipitation. Tubes were centrifuged for 5 min at 14 000 RPM (4 8C), and the protein precipitate removed for digestion. Protein was trypsinized (Promega, Madison, Wisconsin, USA) and purified using a 20-mm filter (Pall Corporation, Ann Arbor, Michigan, USA). Trypsinized peptides were purified using an Oasis mixed-mode weak cation exchange cartridge (Waters, Milford, Massachusetts, USA). Samples were then dehydrated with a Savant ISS 110 SpeedVac Concentrator (Thermo Fisher, Rockford, Illinois, USA) and resuspended in 7 ml of 0.1% formic acid for liquid chromatography-mass spectrometry (MS)/MS analyses.
MS was conducted using a LTQ Velos system that included two alternating peptide traps and a PicoFrit C18 column emitter (New Objective, Woburn, Massachusetts, USA). Samples were resuspended in water containing 0.1% formic acid and injected into the Velos with a linear gradient of acetonitrile (ACN) from 0 to 100% over the course of 200 min. This was followed by two washes: one at 0-40% ACN ramp up and the other linear gradient of ACN for 110 min [42] [43] [44] .
Proteomic analysis and bioinformatics Raw data were converted to mzXML format using MSConvert (ProteoWizard 3.0.6002; Proteowizard Software Foundation; proteowizard.sourceforge.net), and proteomic data were searched with Mascot 2.4.1 [45] using the SwissProt Human sequences from Uniprot (Version Year 2013; www.uniprot.org). Results from the Mascot search engine were analyzed in Scaffold 4.0.5 (Proteome Software, Inc., Portland, Oregon, USA) using a subset search [46] with X!Tandem CYCLONE (2010.12.01.1; The Global Proteome Machine Organization; Open source softrware) [47] and data filters of 5% peptide false discovery rate (FDR) (with 99% peptide confidence), 5% protein FDR (with 99% protein confidence) requiring a minimum of two peptides for protein identification. Protein identifications were further clustered to remove redundancy. Quantitative values were normalized by multiplying the spectral counts for each peptide by a ratio of the average for total spectra from all samples divided by the total spectra for each individual sample. Proteins were retained for further analyses if they were identified in 70% of the samples within each patient group.
Statistical analyses
For descriptive analyses by group, Kruskall-Wallis tests were used for continuous variables and Fisher's exact test for categorical variables. Paired two tailed t tests were performed for calculating change CSF protein levels between baseline (visit 1) and follow-up (visit 2). To account for multiple comparisons, we used the Benjamini-Hochberg correction method that resulted in P values 0.0529 or less considered as statistical significant.
Predictive modeling
Principal components analysis (PCA) was used to derive models that maximized the variance between CSF proteomes based on neurocognitive change group. PCA loadings were derived from spectral counts of proteins, and missing values were set to two spectral counts (just below the lowest detectable limit). PCA was performed using R3.3.4 [48] [49] [50] . Heat maps and hierarchical cluster analysis were performed using the nonlinear minimization package in R [51] . GraphPad PRISM (6.07; La Jolla, California, USA) and R-packages (R Foundation for Statistical Computing, Vienna, Austria) were used for statistical analysis and generation of figures. Ingenuity Pathway Analysis (IPA, Qiagen, Maryland, USA) was performed using the relative fold change for each protein at baseline and follow-up based on quantitative data from proteomic MS. The software was set to the following parameters: Reference set: Ingenuity Knowledge Base (Genes Only), Data Sources: All, Confidence: All, Species: All, Tissues & Cell Lines: All. Canonical pathways with few protein hits were excluded from further analysis. The ratio of the number of hits in a pathway to the total number of reference proteins in the IPA database, and P values were calculated by IPA.
Results
Proteomic evidence for cellular stress, neural damage, and immune activation in HIV-infected patients with cognitive impairment We first determined if there were cross-sectional differences in CSF proteomic profiles of HIV-infected patients classified as normal or impaired at the first visit. For these analyses, we only included proteins that were within detectable limits in a minimum of 70% of the patient samples within each group to ensure that the proteins identified as unique were indeed associated with the group, and not to a small number of individuals within a group. Using the specified criterion, 13 proteins were unique to the impaired group, four to the normal group, and 53 were common to both groups (Table S2 , http:// links.lww.com/QAD/B90). The four proteins found to be unique to the neurocognitive normal group were associated with immune function (Ig-g-chain-2C region), energy metabolism (insulin-like growth factor binding protein 6), and lipid metabolism (Ectonucleotide pyrophosphatase, Apolipoprotein A-II) (Table S2 , http:// links.lww.com/QAD/B90). The 13 proteins unique to the neurocognitive impaired group included markers of neuronal damage (Amyloid beta A4 precursor protein), immune regulation (beta-2-microglobulin, and Ig-gchain-3C region, complement C4-B, and alpha-1-acidic glycoprotein), control of oxidative stress (Superoxide dismutase, Vitamin E binding protein), glycoproteins associated with cell adhesion (Vitronectin, Cadherin-13), structural integrity of muscle tissue (Dystroglycan), plasma and sterol transport (Afamin, Epididymal secretory protein E1, Haptoglobin-related protein), and RNA degradation (RNase I) (Table S2 , http:// links.lww.com/QAD/B90). Of the 53 proteins common between the normal and impaired cognition, 49 of these were decreased in the impaired group (Fig. 1a) . These data suggest that neurocognitive impairment is associated with alterations in the CSF proteome, characterized by induction of proteins associated with cellular stress, damage, and immune activation.
To further explore the relationships between CSF proteomic profiles and neurocognitive status, we used a PCA to determine if the entire CSF proteomic content could be used to separate groups based on neurocognitive status. A pronounced separation was present using a three-component PCA model (PC1 ¼ 37.0%, PC2 ¼ 9.9%, PC3 ¼ 6.2%, PCA ¼ 53.1%) (Fig. 1b) . The primary contributors to PCA separation included proteins involved in wound healing and coagulation (Serpin C1, Fibronectin, and Kininogen-1), immune response (Complement component C1, Alpha-1B-glycoprotein), neuroendocrine function (Chromogranin A, and Cystatin 3), neuronal development (Dickkopf-3 and Neuronal Cell Adhesion Molecule), and glycosylation (B3GNT2) (Fig. 1c) . In this analysis, all impaired patients were correctly classified, but 16 of 89 normal patients were 'incorrectly' clustered with the impaired group. When we stratified according to longitudinal change in cognitive status, we found that all of the 'incorrectly' classified normal patients at baseline developed neurocognitive impairment within 6 months. This result suggests that baseline CSF protein profiles may be prognostic indicators for change in neurocognitive status.
Acute phase and complement cascades are implicated in changing cognitive status We next stratified patients as stably normal, worsening, improving, or stably impaired on the basis of change in cognitive function from the first to the second study visit ($6 months later). A third visit performed $18 months following the baseline visit was used to validate the trajectory of change in cognitive status, as previously described [35, 52] . Using these stratifications, we identified two proteins unique to the stably normal group, and three to the worsening group (Fig. S1 , http:// links.lww.com/QAD/B89). The two proteins unique to the stably normal group were proteins involved in energy metabolism and signaling (Ectonucleotide pyrophosphatase, and Insulin-like growth factor-binding protein 7) (Fig. S1 , http://links.lww.com/QAD/B89). The three proteins unique to the worsening group were associated with cholesterol transport (Epididymal secretory protein E1), redox regulation (Superoxide dismutase), and cell adhesion (Thy-1 membrane glycoprotein) (Fig. S1A and B (Fig. 2c) , and improving groups (PC1 ¼ 56.7%, PC2 ¼ 10.2%, PC3 ¼ 7.2%; PCA ¼ 74.2%) (Fig. 2e) . The top 10 proteins that contributed to PCA separation between stably normal and stably impaired (Fig. 2b) or stable normal and worsening (Fig. 2c) were nearly identical and consisted of proteins involved in neurite development (NRCAM, DKK3), neuroendocrine signaling (Chromogranin-A and Cystatin-C), glycosylation (B3GNT2), immune response (Complement Component-1s, Alpha-1B-glycoprotein), coagulation and adhesion (Kininogen-1 and Fibronectin), and lipid transport (Apolipoprotein-E). The single exception was a protein involved in immune response (Complement component C4-A) that replaced Apolipoprotein-E in the comparison to worsening. Significantly five of these 10 proteins, Alpha-1B-glycoprotein, B3GNT2, Chromagranin-A, Fibronectin, and Kininogen-1, were found above to distinguish baseline neurocognitive function. Only a modest separation was possible between stably impaired and improved groups (Fig. S2A , http://links.lww.com/ QAD/B89); the major contributors to this separation are shown in Fig. S2B , http://links.lww.com/QAD/B89. Using PCA, we were not able to build a model that separated the improving and worsening groups using baseline CSF protein profiles (Fig. S2C and D , http:// links.lww.com/QAD/B89). This might be because of heterogeneity in the worsening group, which could be either normal or impaired at baseline. However, PCA was able to obtain good separation between the stably impaired and improving groups (Fig. S2E and F , http://links.lww.com/QAD/B89), and the improving and worsening groups (Fig. 2SG and H, http:// links.lww.com/QAD/B89) using CSF proteomic profiles obtained from the follow-up visit. We were not able to build a model that separates on the basis of ART (Fig. S10 , http://links.lww.com/QAD/B89). These data suggest that CSF protein profiles at baseline could distinguish patients with impaired (or soon to be impaired) cognitive function from patients with stably normal cognitive function, and the CSF protein profile at follow-up could further distinguish improving from declining cognitive function.
As complex modifications in the proteome are not easily interpreted by investigating the functions of individual proteins, we used IPA to interrogate the CSF proteomic content and identified two integrated signaling pathways that were reciprocally regulated in the worsening and improving groups. In the worsening group, acute phase response and the complement pathway ( Fig. 3a; Figs. S3 and S4, http://links.lww.com/QAD/B89) were positively regulated, whereas evidence of negative regulation of acute phase response and complement cascades was apparent in improving group ( Fig. 3b; Figs. S5 and S6, http://links.lww.com/QAD/B89). Induction of the acute phase response in the worsening group was suggested by the induction of proteins associated with the IL-6 response and the TNFa-associated acute phase response (Fig. S3 , http://links.lww.com/QAD/B89). Involvement of the alternate complement pathway was implicated by increases of serine proteases C3, and complement factor B (Fig. S5 , http://links.lww.com/ QAD/B89). Although C1 was also upregulated, the acute phase response protease inhibitor SERPING1 was also induced, and based on downstream protein expression, (Fig.  S5 , http://links.lww.com/QAD/B89). In Improvers, acute phase and complement pathways were downregulated (Figs. S4 and S6, http://links.lww.com/QAD/ B89). Although these analyses also implicated nuclear receptor signaling and macrophage reactive oxygen species pathways, a number of protein hits in these putative pathways were low and largely overlapped with the acute phase or complement pathways (data not shown).
Longitudinal changes in cerebrospinal fluid proteomic content
We used hierarchical clustering to arrange longitudinal changes in CSF protein content in the worsening group (Fig. 4a) . No groups of proteins that clustered from the first to the second visit were clearly evident, but seven proteins did significantly change between visits when comparing the worsening and stably normal groups. Proteins that increased in abundance were associated with immune function (b-2-microglobulin, Clusterin and Gelsolin), and proteins that decreased in abundance were associated with neuroendocrine function (Chromogranin-A), immune regulation (Vitamin D-binding protein), complement pathway (Plasma protease-C1 inhibitor), and metabolism (insulin-like growth factor binding protein-6) ( Table S3 , http:// links.lww.com/QAD/B90; Fig. S7 , http://links.lww. com/QAD/B89). In addition to these proteins, a large number of proteins showed trends in the worsening group. As each of these more subtle changes in protein expression can work together to modify cell signaling, we used IPA to interrogate the proteomic data obtained from analysis of CSF at the second visit. This analysis showed that induction of the acute phase and complement system that was apparent at the first visit (Fig. 3a) was largely downregulated at the second visit (Fig. 4b) . These results suggest that these pathways are transiently induced early in the progression of cognitive impairment.
A robust change in CSF protein content was apparent in the improving group (Fig. 5a ) with 23 proteins increased, and 21 decreased at the second visit (Table S3, Combined bar charts (P value) and line graphs (ratio) show canonical pathways identified by ingenuity pathway analysis for patients with (a) worsening, and (b) improving cognitive status. The pathways are ranked according to their P value. Orange depicts pathways with increased activity, and blue pathways depict reduced pathway activity. metabolism and transport, neuronal development and neurotrophic functions, neuroendocrine signaling, and immune regulation (Fig. S8A-W , http://links.lww.com/ QAD/B89). The 21 proteins decreased in abundance at the second visit in the improving group included proteins involved in lipolysis, plasma transport, neurite outgrowth, immune and acute phase response, and RNA degradation (Fig. S9A-U , http://links.lww.com/QAD/B89). IPA of the CSF proteomic content at the second for patients with improving cognitive function showed a negative regulation of acute phase and complement systems (Fig. 5b) , suggesting that an active inhibition of these systems begins before measurable improvements in cognitive status, and continues after cognitive status has improved.
Discussion
We found that there was a general reduction in the CSF proteomic content (at both visit 1 and visit 2) in HIVinfected patients with impaired cognition, compared with patients with normal cognition. This observation was made after processing CSF for proteomic analysis by removal of abundant proteins that would normally mask the detection of less abundant proteins. Typically, total CSF protein content is normal, or slightly elevated in HIV-infected patients, suggesting that the lower CSF content of less abundant proteins may normally be masked by the presence of highly abundant proteins such as albumin and IgG. A decrease in the less-abundant CSF proteins may implicate defects of protein transcription/ translation in the CNS of HIV-infected patients with cognitive impairment. As these reductions in lessabundant CSF protein levels were observed prior to cognitive decline (visit 1) and remained after decline (visit 2), this suggests that transcriptional/translational deficits in the CNS could be important contributors to cellular dysfunction and cognitive impairment in HIV-infected patients.
An informatics analysis of the baseline CSF protein content stratified by longitudinal change in neurocognitive performance identified modifications in acute phase and complement pathways as early events that may regulate neurocognitive changes in HIV-infected adults. The complement system plays key roles in regulating the host-defense to pathogens. Depending on the involvement of particular molecular activators, the complement system is induced through three distinct pathways known as the classical, alternative and mannose-binding lectin pathways [53, 54] . All pathways converge on the activation of C3, a central component that is critical for the formation of the terminal membrane attack complex (MAC). The MAC forms a lytic pore in the lipid bilayer of membranes that allows free passage of solutes and water to lyse foreign pathogens and cells. Almost all components of the complement system are produced locally in the brain, but expression in the CNS is tightly controlled to avoid inflammation-associated tissue damage [55, 56] . The classical complement cascade is transiently induced to mediate activity-dependent pruning of inappropriate synapses during development, through antibody-independent binding of C1q to neurons [57] . Other C1q family members have been shown to act as synaptic organizers regulating climbing fiber-Purkinje cell synapses in the cerebellum [58] [59] [60] and to regulate the synaptic localization of kainate receptors in the hippocampus, and postsynaptic delta2 glutamate receptors during synaptic plasticity [58, 61] . These physiological roles for complement cascades in the CNS can become maladaptive with age and in neurodegenerative conditions [62] [63] [64] [65] [66] .
Complement C1q, C3, and C4 have previously been detected in the CSF of HIV-infected patients [67] [68] [69] [70] , and gene expression studies using postmortem human brain tissues have suggested that complement components are strongly upregulated in the neocortex of patients with cognitive impairment and HIVencephalitis, but not in cognitively impaired patients without encephalitis [71] . Our data suggest that complement activation in the CNS of HIV-infected adults may be an early event that promotes neuronal dysfunction.
Although determining the precise underlying cause for the induction of the complement system is not possible, intact HIV virions, Nef, and gp41 (but not Tat, gp120, and gp160) induce complement expression in astrocytes and promote export of C3 [72] . In the simian immunodeficiency virus model of HIV infection, high levels of C1q and C3 were measured in brain of infected nonhuman primates, and both were found deposited on the membrane of neurons, a prerequisite for formation of the MAC. These data support a model in which blips of HIV replication in the CNS may be responsible for induction of the complement system with subsequent neural damage, and worsening cognitive function.
The complement response to viral infection is qualitatively different from the acute phase response elicited by bacterial infections. HIV infection is accompanied by a higher concentration and faster synthesis of positive acute phase proteins, but not by lower concentrations and slower synthesis of negative acute phase proteins [73] . For example, the positive acute phase proteins haptoglobin and haptoglobin-hemoglobin scavenger receptor CD163 levels in HIV-infected patients are positively correlated with viral load [74] and with the progression of HIV infection [75] . Likewise, ceruloplasmin is increased in HIV-infected patients [76] , in association with cognitive impairment [77] , and with decreased oxidative damage in untreated HIV-positive patients [78] . This peculiar acute phase response to viral infection that lacks induction of 'negative' acute phase proteins to limit the inflammatory response may contribute to the low-level chronic inflammation frequently observed in brain and CSF of HIV-infected patients, even when viral replication is suppressed by ART [79, 80] .
Inflammatory cascades are known to cross-talk with cellular stress responses, and with the unfolded protein response to create an integrated stress response that can inhibit protein translation, cellular homeostasis, and cellular response to stress [81] [82] [83] . In the current study, we found a decreased CSF protein content in HIVinfected patients, and recent postmortem studies of brain tissues from HIV-infected patients with cognitive impairment found elevated levels of ER stress proteins BiP and ATF6 [84, 85] . However, other studies have shown that CSF pleocytosis, and/or increased CSF protein content, is apparent in advanced AIDS [86] , in patients with acute CSF viral escape [87] , or with the onset of neurological symptoms [88] . In cases of advanced AIDS, or when evidence for CNS viral replication is apparent, this increased CSF protein content likely reflects damage to the blood-brain barrier, and increased intrathecal albumin and/or IgG [89] . In the current study, we depleted albumin and IgG before proteomic analysis to facilitate the detection of less abundant proteins. Thus, the lower amounts of many CSF proteins in the cognitively impaired individuals in our study most likely reflect lower brain protein production that could be the result of an integrated CNS stress response.
There were several proteins associated with sterol transport increased in the CSF of patients with cognitive impairment including Afamin, and Epididymal secretory protein E1 (NPC1), and NPC1 was one of only three proteins unique to the cognitive worsening group. Hepatocytes are the primary produces of afamin, and abundant concentrations are found in plasma and CSF. Population-based studies have shown that afamin is strongly associated with the prevalence and development of metabolic syndrome [90] [91] [92] . NPC1 regulates the egress of cholesterol from the endosomal/lysosomal compartment. Mutations in this protein are associated with Niemann-Pick Disease that is characterized by the accumulation of sterols and sphingolipids in lysosomal compartments. Mutations in NPC1 have also been reported to be enriched in patients with unexplained early-onset ataxia [93, 94] . Treatments that reduce cholesterol and sphingolipid accumulation increase expression of NPC1 and NPC2 [95] . These data suggest that a metabolic dysregulation is associated with cognitive impairment, and the upregulation of sterol transport proteins during cognitive worsening may be a protective response to cellular damage. Mobilized sterols can be used for tissue repair that require delivery of sterols (such as synaptic structures) [96] .
These data were obtained from a relatively small group of patients selected from $3000 case reviews to be clinically and demographically matched. Although this approach provides a considerable advantage to identify biomarkers that specifically relate to changes in the cognitive status of HIV infected adults, these findings need to be replicated in a larger cohort to determine if variations in demographic and clinical factors modulate the CSF protein biomarkers used to identify acute phase and complement systems.
Our informatics analysis of longitudinal changes CSF protein content suggests that changes in markers of immune function, cell stress, and inflammation in HIVinfected patients with HIV-associated neurocognitive disorders (HAND) may reflect the induction of acute phase and complement systems. The induction of these systems is associated with declines in cognitive function, whereas the downregulation of acute phase and complement systems was associated with improvements in cognitive function, suggesting that modulation of these pathways may be beneficial in HIV-infected patients with HAND.
